CD38 and COVID-19: Both of them showed increased CD38+ expression in HD patients already with mild/asymptomatic COVID-19 and even more with moderate/severe COVID-19, thus providing an effective response to the viral infection and thereby being one explanation for the improved outcome in this cohort.